Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies

During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficac...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 12920 - 12
Main Authors Kutkat, Omnia, Moatasim, Yassmin, Al‐Karmalawy, Ahmed A., Abulkhair, Hamada S., Gomaa, Mokhtar R., El-Taweel, Ahmed N., Abo Shama, Noura M., GabAllah, Mohamed, Mahmoud, Dina B., Kayali, Ghazi, Ali, Mohamed A., Kandeil, Ahmed, Mostafa, Ahmed
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 28.07.2022
Nature Publishing Group
Nature Portfolio
Subjects
631/154
639/638
692/699
Amitriptyline
Antidepressants
Antiviral activity
Antiviral agents
Antiviral drugs
Clinical trials
Coronaviruses
COVID-19
Eating disorders
Headache
Humanities and Social Sciences
Imipramine
Mental depression
Middle East respiratory syndrome
Migraine
multidisciplinary
Neuralgia
Pandemics
Paroxetine
Patients
Prophylaxis
Science
Science (multidisciplinary)
Sertraline
Severe acute respiratory syndrome coronavirus 2
Online AccessGet full text

Cover

Abstract During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (M pro ) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.
AbstractList During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (M pro ) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.
During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (Mpro) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.
Abstract During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (Mpro) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.
During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (Mpro) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (Mpro) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.
ArticleNumber 12920
Author Mahmoud, Dina B.
Al‐Karmalawy, Ahmed A.
Abo Shama, Noura M.
Abulkhair, Hamada S.
Moatasim, Yassmin
Gomaa, Mokhtar R.
Kandeil, Ahmed
Ali, Mohamed A.
Kutkat, Omnia
Mostafa, Ahmed
El-Taweel, Ahmed N.
GabAllah, Mohamed
Kayali, Ghazi
Author_xml – sequence: 1
  givenname: Omnia
  surname: Kutkat
  fullname: Kutkat, Omnia
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 2
  givenname: Yassmin
  surname: Moatasim
  fullname: Moatasim, Yassmin
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 3
  givenname: Ahmed A.
  surname: Al‐Karmalawy
  fullname: Al‐Karmalawy, Ahmed A.
  organization: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt
– sequence: 4
  givenname: Hamada S.
  surname: Abulkhair
  fullname: Abulkhair, Hamada S.
  organization: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University
– sequence: 5
  givenname: Mokhtar R.
  surname: Gomaa
  fullname: Gomaa, Mokhtar R.
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 6
  givenname: Ahmed N.
  surname: El-Taweel
  fullname: El-Taweel, Ahmed N.
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 7
  givenname: Noura M.
  surname: Abo Shama
  fullname: Abo Shama, Noura M.
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 8
  givenname: Mohamed
  surname: GabAllah
  fullname: GabAllah, Mohamed
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 9
  givenname: Dina B.
  surname: Mahmoud
  fullname: Mahmoud, Dina B.
  organization: Pharmaceutics Department, Egyptian Drug Authority, formerly known as National Organization for Drug Control and Research
– sequence: 10
  givenname: Ghazi
  surname: Kayali
  fullname: Kayali, Ghazi
  organization: Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Human Link DMCC
– sequence: 11
  givenname: Mohamed A.
  surname: Ali
  fullname: Ali, Mohamed A.
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 12
  givenname: Ahmed
  surname: Kandeil
  fullname: Kandeil, Ahmed
  email: kandeil_a@hotmail.com
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
– sequence: 13
  givenname: Ahmed
  surname: Mostafa
  fullname: Mostafa, Ahmed
  email: ahmed_elsayed@daad-alumni.de
  organization: Center of Scientific Excellence for Influenza Viruses, National Research Centre
BookMark eNp9ks1u1TAQhS1UREvpC7CyxIZNin_jhAUSqqBUqoSEYG059iT4KrEvdlLpvgWPjHNTAe2i3ng8Pueb0WheopMQAyD0mpJLSnjzLgsq26YijFVUkYZV9TN0xoiQFeOMnfwXn6KLnHekHMlaQdsX6JTLlrBaqDP0-1vsljxjE2Z_55MZsbFrNB9w7LGN0xTDeMD7BNkm34E7Kh2siVzCjM1gfCgEmCANPgzFlGIwBbZkyO-xD7jgUixGtz6yH72N2KVlwAn2S9rHvNryvDgP-RV63psxw8X9fY5-fP70_epLdfv1-ubq421lJVVz1bq2V4RzArRnxPGuV8AaZUUnpeKSUaKEMg1Q5airGa-ZNNRaAUXoiGj5ObrZuC6and4nP5l00NF4fUzENGiTZm9H0Mo4oSjrOLNUcFM3taLWcUVoR7u2k4X1YWPtl24CZyHMZZIPoA9_gv-ph3inW84pIaIA3t4DUvy1QJ715LOFcTQB4pI1q9tSVSjCivTNI-kuLimUUa0q2RAp5Apkm8qmmHOC_m8zlOh1f_S2P7rsjz7uj66LqXlksn42s49r03582so3ay51wgDpX1dPuP4AL2TdtA
CitedBy_id crossref_primary_10_1038_s41598_024_77854_0
crossref_primary_10_1007_s10787_024_01535_7
crossref_primary_10_1002_ardp_202400931
crossref_primary_10_1080_14756366_2022_2135512
crossref_primary_10_1080_17568919_2024_2419363
crossref_primary_10_3390_metabo12111109
crossref_primary_10_1016_j_fbio_2024_105195
crossref_primary_10_1039_D2RA04015H
crossref_primary_10_1080_07391102_2023_2188957
crossref_primary_10_3390_v16030338
crossref_primary_10_1039_D3RA00416C
crossref_primary_10_4155_fmc_2023_0139
crossref_primary_10_1016_j_ejmech_2023_115380
crossref_primary_10_1007_s10787_023_01160_w
crossref_primary_10_1016_j_bioorg_2023_106397
crossref_primary_10_1016_j_bioorg_2024_107105
crossref_primary_10_1016_j_bioorg_2022_106255
crossref_primary_10_1016_j_bioorg_2025_108159
crossref_primary_10_1080_14756366_2023_2202358
crossref_primary_10_4155_fmc_2023_0198
crossref_primary_10_1002_cbdv_202201045
crossref_primary_10_3390_ph16010043
crossref_primary_10_3390_v16040545
crossref_primary_10_1016_j_mcna_2022_09_001
crossref_primary_10_1016_j_lfs_2022_121048
crossref_primary_10_1080_14756366_2023_2171029
crossref_primary_10_1016_j_euroneuro_2023_03_011
crossref_primary_10_1039_D4RA04728A
crossref_primary_10_1016_j_antiviral_2025_106103
crossref_primary_10_31857_S0041377124020069
crossref_primary_10_1080_17460441_2023_2192921
crossref_primary_10_3389_fcimb_2024_1423739
crossref_primary_10_3390_microorganisms11112777
crossref_primary_10_1016_j_bioorg_2023_106789
crossref_primary_10_1186_s13287_024_03889_9
crossref_primary_10_1080_07391102_2023_2167000
crossref_primary_10_1186_s43141_023_00624_4
crossref_primary_10_3390_v16101559
crossref_primary_10_1134_S1990519X24700378
crossref_primary_10_3390_ijms232012235
crossref_primary_10_1186_s43088_024_00513_w
crossref_primary_10_1515_znc_2024_0083
crossref_primary_10_1039_D5NJ00367A
crossref_primary_10_3390_ph16030463
Cites_doi 10.1177/2045125318791944
10.1016/j.heliyon.2020.e05641
10.1097/jcp.0b013e3181bb617
10.1039/D0NJ04088F
10.1016/j.sajb.2021.02.007
10.1038/s41586-020-2179-y
10.1007/BF02123574
10.1016/j.jtcme.2021.05.001
10.1016/j.ejmech.2018.03.004
10.1016/j.bbi.2020.07.037
10.1016/j.compbiomed.2021.105149
10.3390/molecules24173061
10.1002/ardp.202000277
10.1021/acsomega.1c05519
10.1007/s00213-022-06105-9
10.1186/s43141-020-00055-5
10.1016/j.lfs.2021.120185
10.3390/ph13120443
10.1039/D1RA04820A
10.1039/D0NJ03611K
10.1016/j.bbi.2020.05.038
10.1007/s12250-019-00184-3
10.1039/D1NJ02663A
10.1016/j.bioorg.2020.103781
10.1186/s43045-020-00065-6
10.1007/s11030-020-10070-w
10.3390/microorganisms8070991
10.1016/j.ijpharm.2021.121023
10.1016/j.xcrm.2020.100142
10.1016/j.lfs.2020.117592
10.1371/journal.pone.0247679
10.1371/journal.pone.0246454
10.3390/pharmaceutics13030307
10.1128/MRA.00489-20
10.3389/fchem.2021.661230
10.1039/D0RA10674G
10.1371/journal.ppat.1009413
10.1080/07391102.2021.1918256
10.1001/jama.2019.20153
10.1016/j.imu.2021.100604
10.1097/MJT.0000000000001001
10.1016/j.celrep.2018.06.041
10.1016/S2589-7500(20)30086-8
10.1002/ardp.202000237
10.3892/br.2016.807
10.1007/s11030-020-10131-0
10.1016/S2214-109X(21)00448-4
10.1016/S2215-0366(20)30482-X
10.1038/s41586-020-2223-y
10.1016/j.bbi.2020.05.062
10.3390/ijerph16132255
10.1080/17460441.2019.1546691
10.1039/D1NJ02885E
10.1080/07391102.2020.1815584
10.1021/acsptsci.0c00144
10.3390/pathogens10050623
10.3390/horticulturae7100402
10.3390/molecules26216559
10.3201/eid2006.140299
10.3389/fphar.2021.615695
10.1111/bph.12720
10.1080/14756366.2021.2007905
10.1039/D0NJ02844D
10.1128/JVI.79.12.7819-7826.2005
10.3390/molecules26123772
10.1101/pdb.prot087379
10.1002/jbt.22938
ContentType Journal Article
Copyright The Author(s) 2022
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
Copyright_xml – notice: The Author(s) 2022
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-17082-6
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 12
ExternalDocumentID oai_doaj_org_article_7ad4712b32c143a68671cd3701b1b9b5
PMC9331004
10_1038_s41598_022_17082_6
GrantInformation_xml – fundername: National Research Centre
  grantid: MP120801
  funderid: http://dx.doi.org/10.13039/100007787
– fundername: Academy of Scientific Research and Technology
  grantid: 7303; 7371
  funderid: http://dx.doi.org/10.13039/501100002349
– fundername: U.S. Department of Health and Human Services
  grantid: HHSN272201400006C
  funderid: http://dx.doi.org/10.13039/100000016
– fundername: ;
  grantid: 7303; 7371
– fundername: ;
  grantid: HHSN272201400006C
– fundername: ;
  grantid: MP120801
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
7XB
8FK
AARCD
COVID
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c517t-9d9f70330e1f20d3bf7e287c4b55735210747a8e17d1d623625a1cc4ebf7d0493
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:21:27 EDT 2025
Thu Aug 21 14:04:53 EDT 2025
Thu Jul 10 19:01:57 EDT 2025
Wed Aug 13 07:02:45 EDT 2025
Tue Jul 01 04:16:58 EDT 2025
Thu Apr 24 23:12:00 EDT 2025
Fri Feb 21 02:36:58 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-9d9f70330e1f20d3bf7e287c4b55735210747a8e17d1d623625a1cc4ebf7d0493
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-17082-6
PMID 35902647
PQID 2695805454
PQPubID 2041939
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_7ad4712b32c143a68671cd3701b1b9b5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9331004
proquest_miscellaneous_2696864702
proquest_journals_2695805454
crossref_primary_10_1038_s41598_022_17082_6
crossref_citationtrail_10_1038_s41598_022_17082_6
springer_journals_10_1038_s41598_022_17082_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-07-28
PublicationDateYYYYMMDD 2022-07-28
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-28
  day: 28
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Reis, Dos Santos Moreira-Silva, Silva, Thabane, Milagres, Ferreira, Dos Santos, de Souza Campos, Nogueira, de Almeida (CR67) 2022; 10
Indrayanto, Putra, Suhud, Al-Majed (CR56) 2021
Cheung, Poon, Ng, Luk, Sia, Wu, Chan, Yuen, Gordon, Guan, Peiris (CR22) 2005; 79
Al-Rabia, Alhakamy, Ahmed, Eljaaly, Aloafi, Mostafa, Asfour, Aldarmahi, Darwish, Ibrahim, Fahmy (CR5) 2021; 13
Raslan, Taher, Al-Karmalawy, El-Ebeedy, Metwaly, Elkateeb, Ghanem, Elghaish, Abd El Maksoud (CR36) 2021; 45
Zaki, Al-Karmalawy, El-Amier, Ashour (CR40) 2020; 44
Elsayed Khate, El-khouly, Mohamed Abdel-Ba, Mohsen Al-mahallawi, Mahmoud (CR19) 2021; 607
Li, Scherer, Felix, Kuper (CR14) 2021; 16
Farooq, Asghar, Kanwal, Zulqernain (CR60) 2017; 6
Shang, Ye, Shi, Wan, Luo, Aihara, Geng, Auerbach, Li (CR30) 2020; 581
Carpinteiro, Edwards, Hoffmann, Kochs, Gripp, Weigang, Adams, Carpinteiro, Gulbins, Keitsch (CR66) 2020; 1
Gonda, Sharma, Tarazi (CR69) 2019; 14
Alnajjar, Mostafa, Kandeil, Al-Karmalawy (CR4) 2020; 6
Al-Karmalawy, Farid, Mostafa, Ragheb, Mahmoud, Shehata, Shama, GabAllah, Mostafa-Hedeab, Marzouk (CR39) 2021; 26
Elmaaty, Darwish, Khattab, Elhady, Salah, Hamed, Al-Karmalawy, Saleh (CR35) 2021
McConkey, Sobolev, Edelman (CR46) 2002; 83
Ghanem, Emara, Muawia, Abd El Maksoud, Al-Karmalawy, Elshal (CR27) 2020; 44
Omar, Ihmaid (CR38) 2020; 99
Shivanika, Kumar, Ragunathan, Tiwari, Sumitha (CR52) 2020
Hamed, Darwish, Soltane, Chrouda, Mostafa, Abo Shama, Elhady, Abulkhair, Khodir, Elmaaty, Al-karmalawy (CR51) 2021; 11
Tran, Ha, Vu, Nguyen, Latkin, Nathan, McIntyre, Ho, Tam, Ho (CR64) 2019; 16
Guo, Zheng, Shi, Wang, Li, Li, Fromson, Xu, Liu, Xu (CR62) 2020; 88
Mahmoud, Shitu, Mostafa (CR3) 2020; 18
Elmaaty, Darwish, Chrouda, Boseila, Tantawy, Elhady, Shaik, Mustafa, Al-karmalawy (CR53) 2021; 7
Lee, Subramaniapillai, Brietzke, Mansur, Ho, Yim, McIntyre (CR59) 2018; 8
Nogo, Jasrai, Kim, Nasri, Ceban, Lui, Rosenblat, Vinberg, Ho, McIntyre (CR70) 2022; 239
Elia, Al-Karmalawy, Nasr, Elshal (CR29) 2021; 36
Kandeil, Mostafa, El-Shesheny, Shehata, Roshdy, Ahmed, Gomaa, Taweel, Kayed, Mahmoud (CR20) 2020; 9
Mazza, De Lorenzo, Conte, Poletti, Vai, Bollettini, Melloni, Furlan, Ciceri, Rovere-Querini, Benedetti (CR61) 2020; 89
Shoala, Al-Karmalawy, Germoush, Alshamrani, Abdein, Awad (CR42) 2021; 7
Chu, Poon, Gomaa, Shehata, Perera, Abu Zeid, El Rifay, Siu, Guan, Webby (CR21) 2014; 20
Sanders, Monogue, Jodlowski, Cutrell (CR58) 2020; 323
Ezzat, Bayoumi, Sherbiny, El-Morsy, Ghiaty, Alswah, Abulkhair (CR37) 2020; 25
Gomaa, El Rifay, Shehata, Kandeil, Nabil Kamel, Marouf, GabAllah, El Taweel, Kayed, Kutkat (CR25) 2021; 17
Tobita (CR23) 1975; 162
Diab, Abdelsamii, Abd-Elaal, Al-Karmalawy, AboDya (CR50) 2021; 45
Elebeedy, Badawy, Elmaaty, Saleh, Kandeil, Ghanem, Kutkat, Alnajjar (CR54) 2021; 141
Alnazly, Khraisat, Al-Bashaireh, Bryant (CR13) 2021; 16
Khalifa, Al-Karmalawy, Elkaeed, Nafie, Tantawy, Eissa, Mahdy (CR55) 2022; 37
Brogi (CR10) 2019; 24
Abo Elmaaty, Hamed, Ismail, Elkaeed, Abulkhair, Khattab, Al-Karmalawy (CR43) 2021; 26
Guardiola-Lemaitre, De Bodinat, Delagrange, Millan, Munoz, Mocaër (CR68) 2014; 171
Zhang, Zhou, Wang, Li, Jiang, Jia, Wang, Fan, Wang, Shi (CR32) 2018; 24
Zaki, Ashour, Elhady, Darwish, Al-Karmalawy (CR47) 2021; 12
Thorlund, Dron, Park, Hsu, Forrest, Mills (CR57) 2020; 2
Alsharji (CR12) 2020; 27
Al-Karmalawy, Khattab (CR9) 2020; 44
Yuan, Li, Liu, Cai, Song, Zhao, Hu, Li, Chen, Zhang (CR63) 2020; 88
Nobile, Durand, Olie, Guillaume, Moles, Haffen, Courtet (CR65) 2021; 12
Kankanamalage, Kim, Damalanka, Rathnayake, Fehr, Mehzabeen, Battaile, Lovell, Lushington, Perlman (CR33) 2018; 150
Turky, Bayoumi, Sherbiny, El-Adl, Abulkhair (CR44) 2021; 25
Mostafa, Kandeil, Shehata, El Shesheny, Samy, Kayali, Ali (CR1) 2020; 8
Hazem, Antar, Nafea, Al-Karmalawy, Saleh, El-Azab (CR48) 2021; 288
Sarhan, Ashour, Al-Karmalawy (CR7) 2021; 24
Elmaaty, Alnajjar, Hamed, Khattab, Khalifa, Al-Karmalawy (CR11) 2021; 11
Al-Karmalawy, Dahab, Metwaly, Elhady, Elkaeed, Eissa, Darwish (CR6) 2021; 9
Soltane, Chrouda, Mostafa, Al-Karmalawy, Chouaïb, Dhahri, Pashameah, Alasiri, Kutkat, Shehata (CR41) 2021; 10
da Rosa, Machado, Serafin, Bottega, Foletto, Coelho, Hörner (CR17) 2020; 27
López-Muñoz, Alamo, Juckel, Assion (CR16) 2007; 27
Zhang, Lei, Xie, Li, Liu, Liu, Huang, Xiao, Wang (CR18) 2020; 35
Eliaa, Al-Karmalawy, Saleh, Elshal (CR34) 2020; 3
Jin, Du, Xu, Deng, Liu, Zhao, Zhang, Li, Zhang, Peng (CR31) 2020; 582
CR26
Alesawy, Al-Karmalawy, Elkaeed, Alswah, Belal, Taghour, Eissa (CR45) 2020; 354
CR24
Samra, Soliman, Zaki, Ashour, Al-Karmalawy, Hassan, Zaghloul (CR28) 2021; 139
Elfiky (CR2) 2020; 253
Fancourt, Steptoe, Bu (CR15) 2021; 8
El-Shershaby, El-Gamal, Bayoumi, El-Adl, Ahmed, Abulkhair (CR49) 2021; 354
Mostafa, Kandeil, AMM Elshaier, Kutkat, Moatasim, Rashad, Shehata, Gomaa, Mahrous, Mahmoud, GabAllah (CR8) 2020; 13
RM Samra (17082_CR28) 2021; 139
D Elebeedy (17082_CR54) 2021; 141
D Fancourt (17082_CR15) 2021; 8
E Alnazly (17082_CR13) 2021; 16
T Shoala (17082_CR42) 2021; 7
X Gonda (17082_CR69) 2019; 14
S Zhang (17082_CR32) 2018; 24
17082_CR24
MR Gomaa (17082_CR25) 2021; 17
17082_CR26
Y Lee (17082_CR59) 2018; 8
AA Elmaaty (17082_CR35) 2021
RM Hazem (17082_CR48) 2021; 288
MM Khalifa (17082_CR55) 2022; 37
F López-Muñoz (17082_CR16) 2007; 27
A Ghanem (17082_CR27) 2020; 44
B Guardiola-Lemaitre (17082_CR68) 2014; 171
G Indrayanto (17082_CR56) 2021
G Reis (17082_CR67) 2022; 10
AA Elmaaty (17082_CR53) 2021; 7
BJ McConkey (17082_CR46) 2002; 83
A Turky (17082_CR44) 2021; 25
K Tobita (17082_CR23) 1975; 162
MH El-Shershaby (17082_CR49) 2021; 354
RK Farooq (17082_CR60) 2017; 6
Y Li (17082_CR14) 2021; 16
TF da Rosa (17082_CR17) 2020; 27
AM Omar (17082_CR38) 2020; 99
MW Al-Rabia (17082_CR5) 2021; 13
HG Ezzat (17082_CR37) 2020; 25
AA Al-Karmalawy (17082_CR9) 2020; 44
AA Elfiky (17082_CR2) 2020; 253
AA Al-Karmalawy (17082_CR6) 2021; 9
D Nogo (17082_CR70) 2022; 239
S Elsayed Khate (17082_CR19) 2021; 607
ACG Kankanamalage (17082_CR33) 2018; 150
R Soltane (17082_CR41) 2021; 10
MA Raslan (17082_CR36) 2021; 45
A Carpinteiro (17082_CR66) 2020; 1
RT Diab (17082_CR50) 2021; 45
R Alnajjar (17082_CR4) 2020; 6
SG Elia (17082_CR29) 2021; 36
K Thorlund (17082_CR57) 2020; 2
Z Jin (17082_CR31) 2020; 582
CY Cheung (17082_CR22) 2005; 79
MS Alesawy (17082_CR45) 2020; 354
A Abo Elmaaty (17082_CR43) 2021; 26
Q Guo (17082_CR62) 2020; 88
A Mostafa (17082_CR8) 2020; 13
DB Mahmoud (17082_CR3) 2020; 18
A Kandeil (17082_CR20) 2020; 9
B Nobile (17082_CR65) 2021; 12
AA Al-Karmalawy (17082_CR39) 2021; 26
AA Zaki (17082_CR47) 2021; 12
MIA Hamed (17082_CR51) 2021; 11
AA Zaki (17082_CR40) 2020; 44
MG Mazza (17082_CR61) 2020; 89
SG Eliaa (17082_CR34) 2020; 3
L Zhang (17082_CR18) 2020; 35
DKW Chu (17082_CR21) 2014; 20
B Yuan (17082_CR63) 2020; 88
AA Elmaaty (17082_CR11) 2021; 11
J Shang (17082_CR30) 2020; 581
C Shivanika (17082_CR52) 2020
AA Sarhan (17082_CR7) 2021; 24
KE Alsharji (17082_CR12) 2020; 27
A Mostafa (17082_CR1) 2020; 8
JM Sanders (17082_CR58) 2020; 323
BX Tran (17082_CR64) 2019; 16
S Brogi (17082_CR10) 2019; 24
References_xml – volume: 8
  start-page: 337
  year: 2018
  end-page: 348
  ident: CR59
  article-title: Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression
  publication-title: Ther. Adv. Psychopharmacol.
  doi: 10.1177/2045125318791944
– volume: 6
  start-page: e05641
  year: 2020
  ident: CR4
  article-title: Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2020.e05641
– volume: 27
  start-page: 555
  year: 2007
  end-page: 559
  ident: CR16
  article-title: Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors
  publication-title: J. Clin. Psychopharmacol.
  doi: 10.1097/jcp.0b013e3181bb617
– volume: 44
  start-page: 17374
  year: 2020
  end-page: 17381
  ident: CR27
  article-title: Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K/AKT/mTOR pathway and inhibition of topoisomerase II: in vitro and molecular docking studies
  publication-title: New J. Chem.
  doi: 10.1039/D0NJ04088F
– volume: 139
  start-page: 210
  year: 2021
  end-page: 216
  ident: CR28
  article-title: Bioassay-guided isolation of a new cytotoxic ceramide from L
  publication-title: S. Afr. J. Bot.
  doi: 10.1016/j.sajb.2021.02.007
– volume: 581
  start-page: 221
  year: 2020
  end-page: 224
  ident: CR30
  article-title: Structural basis of receptor recognition by SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2179-y
– volume: 162
  start-page: 23
  year: 1975
  end-page: 27
  ident: CR23
  article-title: Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses
  publication-title: Med. Microbiol. Immunol.
  doi: 10.1007/BF02123574
– volume: 12
  start-page: 16
  year: 2021
  end-page: 34
  ident: CR47
  article-title: Calendulaglycoside a showing potential activity against SARS-CoV-2 main protease: molecular docking, molecular dynamics, and SAR studies
  publication-title: J. Tradit. Complement. Med.
  doi: 10.1016/j.jtcme.2021.05.001
– volume: 150
  start-page: 334
  year: 2018
  end-page: 346
  ident: CR33
  article-title: Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.03.004
– volume: 89
  start-page: 594
  year: 2020
  end-page: 600
  ident: CR61
  article-title: Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2020.07.037
– volume: 141
  start-page: 105149
  year: 2021
  ident: CR54
  article-title: Abd El Maksoud AI, Al-karmalawy AA: In vitro and computational insights revealing the potential inhibitory effect of Tanshinone IIA against influenza A virus
  publication-title: Comput. Biol. Med.
  doi: 10.1016/j.compbiomed.2021.105149
– volume: 24
  start-page: 3061
  year: 2019
  ident: CR10
  article-title: Computational approaches for drug discovery
  publication-title: Molecules
  doi: 10.3390/molecules24173061
– volume: 354
  start-page: 2000277
  year: 2021
  ident: CR49
  article-title: Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives
  publication-title: Arch. Pharm.
  doi: 10.1002/ardp.202000277
– volume: 7
  start-page: 875
  year: 2021
  end-page: 899
  ident: CR53
  article-title: In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity
  publication-title: ACS Omega
  doi: 10.1021/acsomega.1c05519
– volume: 239
  start-page: 2011
  year: 2022
  end-page: 2039
  ident: CR70
  article-title: The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-022-06105-9
– volume: 18
  start-page: 35
  year: 2020
  end-page: 35
  ident: CR3
  article-title: Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
  publication-title: J. Genet. Eng. Biotechnol.
  doi: 10.1186/s43141-020-00055-5
– volume: 288
  start-page: 120185
  year: 2021
  ident: CR48
  article-title: Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2021.120185
– volume: 13
  start-page: 443
  year: 2020
  ident: CR8
  article-title: FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2
  publication-title: Pharmaceuticals
  doi: 10.3390/ph13120443
– volume: 11
  start-page: 35536
  year: 2021
  end-page: 35558
  ident: CR51
  article-title: β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization
  publication-title: RSC Adv.
  doi: 10.1039/D1RA04820A
– volume: 44
  start-page: 16752
  year: 2020
  end-page: 16758
  ident: CR40
  article-title: Molecular docking reveals the potential of isolated compounds to inhibit COVID-19 virus main protease
  publication-title: New J. Chem.
  doi: 10.1039/D0NJ03611K
– volume: 88
  start-page: 17
  year: 2020
  end-page: 27
  ident: CR62
  article-title: Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2020.05.038
– volume: 35
  start-page: 235
  year: 2020
  end-page: 239
  ident: CR18
  article-title: Screening and identification of marburg virus entry inhibitors using approved drugs
  publication-title: Virol. Sin.
  doi: 10.1007/s12250-019-00184-3
– volume: 45
  start-page: 22216
  year: 2021
  end-page: 22233
  ident: CR36
  article-title: (L.) A. Chev. leaves: isolation, HPLC/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking
  publication-title: New J. Chem.
  doi: 10.1039/D1NJ02663A
– volume: 99
  start-page: 103781
  year: 2020
  ident: CR38
  article-title: Habib E-SE, Althagfan SS, Ahmed S, Abulkhair HS, Ahmed HE: The rational design, synthesis, and antimicrobial investigation of 2-Amino-4-Methylthiazole analogues inhibitors of GlcN-6-P synthase
  publication-title: Bioorgan. Chem.
  doi: 10.1016/j.bioorg.2020.103781
– volume: 27
  start-page: 60
  year: 2020
  ident: CR12
  article-title: Anxiety and depression during the COVID-19 pandemic in Kuwait: the importance of physical activity
  publication-title: Middle East Curr. Psychiatry
  doi: 10.1186/s43045-020-00065-6
– volume: 25
  start-page: 291
  year: 2020
  end-page: 306
  ident: CR37
  article-title: Design, synthesis, and molecular docking studies of new [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as potential A2B receptor antagonists
  publication-title: Mol. Divers.
  doi: 10.1007/s11030-020-10070-w
– volume: 8
  start-page: 991
  year: 2020
  ident: CR1
  article-title: Middle east respiratory syndrome coronavirus (MERS-CoV): state of the science
  publication-title: Microorganisms
  doi: 10.3390/microorganisms8070991
– volume: 607
  start-page: 121023
  year: 2021
  ident: CR19
  article-title: Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2021.121023
– volume: 1
  start-page: 100142
  year: 2020
  ident: CR66
  article-title: Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2020.100142
– volume: 253
  start-page: 117592
  year: 2020
  ident: CR2
  article-title: Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.117592
– volume: 16
  start-page: e0247679
  year: 2021
  ident: CR13
  article-title: Anxiety, depression, stress, fear and social support during COVID-19 pandemic among Jordanian healthcare workers
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0247679
– ident: CR26
– volume: 16
  start-page: e0246454
  year: 2021
  ident: CR14
  article-title: Prevalence of depression, anxiety and post-traumatic stress disorder in health care workers during the COVID-19 pandemic: a systematic review and meta-analysis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0246454
– volume: 13
  start-page: 307
  year: 2021
  ident: CR5
  article-title: Repurposing of sitagliptin-melittin optimized nanoformula against SARS-CoV-2; antiviral screening and molecular docking studies
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13030307
– volume: 9
  start-page: e00489
  year: 2020
  end-page: e420
  ident: CR20
  article-title: Coding-complete genome sequences of two SARS-CoV-2 isolates from Egypt
  publication-title: Microbiol. Resour. Announc.
  doi: 10.1128/MRA.00489-20
– volume: 9
  start-page: 661230
  year: 2021
  ident: CR6
  article-title: Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2021.661230
– volume: 11
  start-page: 10027
  year: 2021
  end-page: 10042
  ident: CR11
  article-title: Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study
  publication-title: RSC Adv.
  doi: 10.1039/D0RA10674G
– volume: 83
  start-page: 845
  year: 2002
  end-page: 856
  ident: CR46
  article-title: The performance of current methods in ligand–protein docking
  publication-title: Curr. Sci.
– volume: 17
  start-page: e1009413
  year: 2021
  ident: CR25
  article-title: Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: results of a community-based cohort
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1009413
– volume: 36
  start-page: e22938
  year: 2021
  ident: CR29
  article-title: Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: in vitro and molecular docking study
  publication-title: J. Biochem. Mol. Toxicol.
– year: 2021
  ident: CR35
  article-title: In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins
  publication-title: J. Biomol. Struct. Dyn.
  doi: 10.1080/07391102.2021.1918256
– volume: 323
  start-page: 1824
  year: 2020
  end-page: 1836
  ident: CR58
  article-title: Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review
  publication-title: JAMA
  doi: 10.1001/jama.2019.20153
– volume: 24
  start-page: 100604
  year: 2021
  ident: CR7
  article-title: The journey of antimalarial drugs against SARS-CoV-2: review article
  publication-title: Inform. Med. Unlocked
  doi: 10.1016/j.imu.2021.100604
– volume: 27
  start-page: e528
  year: 2020
  end-page: e532
  ident: CR17
  article-title: Repositioning or redirection of antidepressant drugs in the treatment of bacterial and fungal infections
  publication-title: Am. J. Ther.
  doi: 10.1097/MJT.0000000000001001
– volume: 24
  start-page: 441
  year: 2018
  end-page: 452
  ident: CR32
  article-title: Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2018.06.041
– volume: 2
  start-page: e286
  year: 2020
  end-page: e287
  ident: CR57
  article-title: A real-time dashboard of clinical trials for COVID-19
  publication-title: Lancet Digit. Health
  doi: 10.1016/S2589-7500(20)30086-8
– volume: 354
  start-page: e2000237
  year: 2020
  ident: CR45
  article-title: Design and discovery of new 1, 2, 4-triazolo [4, 3-c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors
  publication-title: Arch. Pharm.
  doi: 10.1002/ardp.202000237
– volume: 6
  start-page: 15
  year: 2017
  end-page: 20
  ident: CR60
  article-title: Role of inflammatory cytokines in depression: focus on interleukin-1β
  publication-title: Biomed. Rep.
  doi: 10.3892/br.2016.807
– volume: 25
  start-page: 403
  year: 2021
  end-page: 420
  ident: CR44
  article-title: Unravelling the anticancer potency of 1,2,4-triazole-N-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies
  publication-title: Mol. Divers.
  doi: 10.1007/s11030-020-10131-0
– volume: 10
  start-page: e42
  year: 2022
  end-page: e51
  ident: CR67
  article-title: Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
  publication-title: Lancet Glob. Health
  doi: 10.1016/S2214-109X(21)00448-4
– volume: 8
  start-page: 141
  year: 2021
  end-page: 149
  ident: CR15
  article-title: Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(20)30482-X
– volume: 582
  start-page: 289
  year: 2020
  end-page: 293
  ident: CR31
  article-title: Structure of M pro from SARS-CoV-2 and discovery of its inhibitors
  publication-title: Nature
  doi: 10.1038/s41586-020-2223-y
– volume: 88
  start-page: 39
  year: 2020
  end-page: 43
  ident: CR63
  article-title: Correlation between immune response and self-reported depression during convalescence from COVID-19
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2020.05.062
– volume: 16
  start-page: 2255
  year: 2019
  ident: CR64
  article-title: Indices of change, expectations, and popularity of biological treatments for major depressive disorder between 1988 and 2017: a scientometric analysis
  publication-title: Int. J. Environ. Res. Public Health
  doi: 10.3390/ijerph16132255
– volume: 14
  start-page: 81
  year: 2019
  end-page: 89
  ident: CR69
  article-title: Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
  publication-title: Expert Opin. Drug Discov.
  doi: 10.1080/17460441.2019.1546691
– volume: 45
  start-page: 21657
  year: 2021
  end-page: 21669
  ident: CR50
  article-title: Design and synthesis of a new series of 3,5-disubstituted-1,2,4-oxadiazoles as potential colchicine binding site inhibitors: antiproliferative activity, molecular docking, and SAR studies
  publication-title: New J. Chem.
  doi: 10.1039/D1NJ02885E
– year: 2020
  ident: CR52
  article-title: Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease
  publication-title: J. Biomol. Struct. Dyn.
  doi: 10.1080/07391102.2020.1815584
– volume: 3
  start-page: 1330
  year: 2020
  end-page: 1338
  ident: CR34
  article-title: Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mtor pathway and inhibition of calmodulin: in vitro and molecular docking studies
  publication-title: ACS Pharmacol. Transl. Sci.
  doi: 10.1021/acsptsci.0c00144
– volume: 10
  start-page: 623
  year: 2021
  ident: CR41
  article-title: Strong inhibitory activity and action modes of synthetic maslinic acid derivative on highly pathogenic coronaviruses: COVID-19 drug candidate
  publication-title: Pathogens
  doi: 10.3390/pathogens10050623
– volume: 7
  start-page: 402
  year: 2021
  ident: CR42
  article-title: Nanobiotechnological approaches to enhance potato resistance against potato leafroll virus (PLRV) using glycyrrhizic acid ammonium salt and salicylic acid nanoparticles
  publication-title: Horticulturae
  doi: 10.3390/horticulturae7100402
– volume: 26
  start-page: 6559
  year: 2021
  ident: CR39
  article-title: Naturally available flavonoid aglycones as potential antiviral drug candidates against SARS-CoV-2
  publication-title: Molecules
  doi: 10.3390/molecules26216559
– volume: 20
  start-page: 1049
  year: 2014
  end-page: 1053
  ident: CR21
  article-title: MERS coronaviruses in dromedary camels, Egypt
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2006.140299
– volume: 12
  start-page: 615695
  year: 2021
  ident: CR65
  article-title: The anti-inflammatory effect of the tricyclic antidepressant clomipramine and its high penetration in the brain might be useful to prevent the psychiatric consequences of SARS-CoV-2 infection
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.615695
– volume: 171
  start-page: 3604
  year: 2014
  end-page: 3619
  ident: CR68
  article-title: Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12720
– volume: 37
  start-page: 299
  year: 2022
  end-page: 314
  ident: CR55
  article-title: Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies
  publication-title: J. Enzyme Inhib. Med. Chem.
  doi: 10.1080/14756366.2021.2007905
– start-page: 273
  year: 2021
  end-page: 307
  ident: CR56
  article-title: Chapter 6: Validation of in-vitro bioassay methods: application in herbal drug research
  publication-title: Profiles of Drug Substances, Excipients and Related Methodology
– volume: 44
  start-page: 13990
  year: 2020
  end-page: 13996
  ident: CR9
  article-title: Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor
  publication-title: New J. Chem.
  doi: 10.1039/D0NJ02844D
– volume: 79
  start-page: 7819
  year: 2005
  end-page: 7826
  ident: CR22
  article-title: Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.12.7819-7826.2005
– ident: CR24
– volume: 26
  start-page: 3772
  year: 2021
  ident: CR43
  article-title: Computational insights on the potential of some NSAIDs for treating COVID-19: priority set and lead optimization
  publication-title: Molecules
  doi: 10.3390/molecules26123772
– volume: 6
  start-page: e05641
  year: 2020
  ident: 17082_CR4
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2020.e05641
– volume: 10
  start-page: 623
  year: 2021
  ident: 17082_CR41
  publication-title: Pathogens
  doi: 10.3390/pathogens10050623
– volume: 16
  start-page: e0247679
  year: 2021
  ident: 17082_CR13
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0247679
– volume: 44
  start-page: 16752
  year: 2020
  ident: 17082_CR40
  publication-title: New J. Chem.
  doi: 10.1039/D0NJ03611K
– volume: 1
  start-page: 100142
  year: 2020
  ident: 17082_CR66
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2020.100142
– volume: 354
  start-page: e2000237
  year: 2020
  ident: 17082_CR45
  publication-title: Arch. Pharm.
  doi: 10.1002/ardp.202000237
– volume: 27
  start-page: e528
  year: 2020
  ident: 17082_CR17
  publication-title: Am. J. Ther.
  doi: 10.1097/MJT.0000000000001001
– volume: 239
  start-page: 2011
  year: 2022
  ident: 17082_CR70
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-022-06105-9
– volume: 141
  start-page: 105149
  year: 2021
  ident: 17082_CR54
  publication-title: Comput. Biol. Med.
  doi: 10.1016/j.compbiomed.2021.105149
– ident: 17082_CR24
  doi: 10.1101/pdb.prot087379
– volume: 150
  start-page: 334
  year: 2018
  ident: 17082_CR33
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.03.004
– year: 2020
  ident: 17082_CR52
  publication-title: J. Biomol. Struct. Dyn.
  doi: 10.1080/07391102.2020.1815584
– volume: 24
  start-page: 100604
  year: 2021
  ident: 17082_CR7
  publication-title: Inform. Med. Unlocked
  doi: 10.1016/j.imu.2021.100604
– volume: 83
  start-page: 845
  year: 2002
  ident: 17082_CR46
  publication-title: Curr. Sci.
– volume: 3
  start-page: 1330
  year: 2020
  ident: 17082_CR34
  publication-title: ACS Pharmacol. Transl. Sci.
  doi: 10.1021/acsptsci.0c00144
– ident: 17082_CR26
– volume: 139
  start-page: 210
  year: 2021
  ident: 17082_CR28
  publication-title: S. Afr. J. Bot.
  doi: 10.1016/j.sajb.2021.02.007
– volume: 44
  start-page: 13990
  year: 2020
  ident: 17082_CR9
  publication-title: New J. Chem.
  doi: 10.1039/D0NJ02844D
– volume: 89
  start-page: 594
  year: 2020
  ident: 17082_CR61
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2020.07.037
– volume: 7
  start-page: 402
  year: 2021
  ident: 17082_CR42
  publication-title: Horticulturae
  doi: 10.3390/horticulturae7100402
– volume: 12
  start-page: 615695
  year: 2021
  ident: 17082_CR65
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.615695
– volume: 9
  start-page: e00489
  year: 2020
  ident: 17082_CR20
  publication-title: Microbiol. Resour. Announc.
  doi: 10.1128/MRA.00489-20
– volume: 9
  start-page: 661230
  year: 2021
  ident: 17082_CR6
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2021.661230
– volume: 24
  start-page: 3061
  year: 2019
  ident: 17082_CR10
  publication-title: Molecules
  doi: 10.3390/molecules24173061
– volume: 582
  start-page: 289
  year: 2020
  ident: 17082_CR31
  publication-title: Nature
  doi: 10.1038/s41586-020-2223-y
– volume: 35
  start-page: 235
  year: 2020
  ident: 17082_CR18
  publication-title: Virol. Sin.
  doi: 10.1007/s12250-019-00184-3
– volume: 13
  start-page: 307
  year: 2021
  ident: 17082_CR5
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13030307
– volume: 607
  start-page: 121023
  year: 2021
  ident: 17082_CR19
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2021.121023
– volume: 18
  start-page: 35
  year: 2020
  ident: 17082_CR3
  publication-title: J. Genet. Eng. Biotechnol.
  doi: 10.1186/s43141-020-00055-5
– volume: 36
  start-page: e22938
  year: 2021
  ident: 17082_CR29
  publication-title: J. Biochem. Mol. Toxicol.
  doi: 10.1002/jbt.22938
– volume: 8
  start-page: 337
  year: 2018
  ident: 17082_CR59
  publication-title: Ther. Adv. Psychopharmacol.
  doi: 10.1177/2045125318791944
– volume: 323
  start-page: 1824
  year: 2020
  ident: 17082_CR58
  publication-title: JAMA
  doi: 10.1001/jama.2019.20153
– volume: 26
  start-page: 3772
  year: 2021
  ident: 17082_CR43
  publication-title: Molecules
  doi: 10.3390/molecules26123772
– volume: 11
  start-page: 10027
  year: 2021
  ident: 17082_CR11
  publication-title: RSC Adv.
  doi: 10.1039/D0RA10674G
– volume: 27
  start-page: 555
  year: 2007
  ident: 17082_CR16
  publication-title: J. Clin. Psychopharmacol.
  doi: 10.1097/jcp.0b013e3181bb617
– volume: 171
  start-page: 3604
  year: 2014
  ident: 17082_CR68
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12720
– volume: 24
  start-page: 441
  year: 2018
  ident: 17082_CR32
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2018.06.041
– year: 2021
  ident: 17082_CR35
  publication-title: J. Biomol. Struct. Dyn.
  doi: 10.1080/07391102.2021.1918256
– volume: 11
  start-page: 35536
  year: 2021
  ident: 17082_CR51
  publication-title: RSC Adv.
  doi: 10.1039/D1RA04820A
– volume: 6
  start-page: 15
  year: 2017
  ident: 17082_CR60
  publication-title: Biomed. Rep.
  doi: 10.3892/br.2016.807
– volume: 45
  start-page: 22216
  year: 2021
  ident: 17082_CR36
  publication-title: New J. Chem.
  doi: 10.1039/D1NJ02663A
– volume: 79
  start-page: 7819
  year: 2005
  ident: 17082_CR22
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.12.7819-7826.2005
– start-page: 273
  volume-title: Profiles of Drug Substances, Excipients and Related Methodology
  year: 2021
  ident: 17082_CR56
– volume: 14
  start-page: 81
  year: 2019
  ident: 17082_CR69
  publication-title: Expert Opin. Drug Discov.
  doi: 10.1080/17460441.2019.1546691
– volume: 88
  start-page: 39
  year: 2020
  ident: 17082_CR63
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2020.05.062
– volume: 25
  start-page: 403
  year: 2021
  ident: 17082_CR44
  publication-title: Mol. Divers.
  doi: 10.1007/s11030-020-10131-0
– volume: 37
  start-page: 299
  year: 2022
  ident: 17082_CR55
  publication-title: J. Enzyme Inhib. Med. Chem.
  doi: 10.1080/14756366.2021.2007905
– volume: 12
  start-page: 16
  year: 2021
  ident: 17082_CR47
  publication-title: J. Tradit. Complement. Med.
  doi: 10.1016/j.jtcme.2021.05.001
– volume: 253
  start-page: 117592
  year: 2020
  ident: 17082_CR2
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.117592
– volume: 581
  start-page: 221
  year: 2020
  ident: 17082_CR30
  publication-title: Nature
  doi: 10.1038/s41586-020-2179-y
– volume: 88
  start-page: 17
  year: 2020
  ident: 17082_CR62
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2020.05.038
– volume: 20
  start-page: 1049
  year: 2014
  ident: 17082_CR21
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2006.140299
– volume: 13
  start-page: 443
  year: 2020
  ident: 17082_CR8
  publication-title: Pharmaceuticals
  doi: 10.3390/ph13120443
– volume: 16
  start-page: 2255
  year: 2019
  ident: 17082_CR64
  publication-title: Int. J. Environ. Res. Public Health
  doi: 10.3390/ijerph16132255
– volume: 8
  start-page: 141
  year: 2021
  ident: 17082_CR15
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(20)30482-X
– volume: 7
  start-page: 875
  year: 2021
  ident: 17082_CR53
  publication-title: ACS Omega
  doi: 10.1021/acsomega.1c05519
– volume: 354
  start-page: 2000277
  year: 2021
  ident: 17082_CR49
  publication-title: Arch. Pharm.
  doi: 10.1002/ardp.202000277
– volume: 45
  start-page: 21657
  year: 2021
  ident: 17082_CR50
  publication-title: New J. Chem.
  doi: 10.1039/D1NJ02885E
– volume: 8
  start-page: 991
  year: 2020
  ident: 17082_CR1
  publication-title: Microorganisms
  doi: 10.3390/microorganisms8070991
– volume: 44
  start-page: 17374
  year: 2020
  ident: 17082_CR27
  publication-title: New J. Chem.
  doi: 10.1039/D0NJ04088F
– volume: 16
  start-page: e0246454
  year: 2021
  ident: 17082_CR14
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0246454
– volume: 26
  start-page: 6559
  year: 2021
  ident: 17082_CR39
  publication-title: Molecules
  doi: 10.3390/molecules26216559
– volume: 10
  start-page: e42
  year: 2022
  ident: 17082_CR67
  publication-title: Lancet Glob. Health
  doi: 10.1016/S2214-109X(21)00448-4
– volume: 99
  start-page: 103781
  year: 2020
  ident: 17082_CR38
  publication-title: Bioorgan. Chem.
  doi: 10.1016/j.bioorg.2020.103781
– volume: 288
  start-page: 120185
  year: 2021
  ident: 17082_CR48
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2021.120185
– volume: 25
  start-page: 291
  year: 2020
  ident: 17082_CR37
  publication-title: Mol. Divers.
  doi: 10.1007/s11030-020-10070-w
– volume: 2
  start-page: e286
  year: 2020
  ident: 17082_CR57
  publication-title: Lancet Digit. Health
  doi: 10.1016/S2589-7500(20)30086-8
– volume: 27
  start-page: 60
  year: 2020
  ident: 17082_CR12
  publication-title: Middle East Curr. Psychiatry
  doi: 10.1186/s43045-020-00065-6
– volume: 17
  start-page: e1009413
  year: 2021
  ident: 17082_CR25
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1009413
– volume: 162
  start-page: 23
  year: 1975
  ident: 17082_CR23
  publication-title: Med. Microbiol. Immunol.
  doi: 10.1007/BF02123574
SSID ssj0000529419
Score 2.5461493
Snippet During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic...
Abstract During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and...
SourceID doaj
pubmedcentral
proquest
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 12920
SubjectTerms 631/154
639/638
692/699
Amitriptyline
Antidepressants
Antiviral activity
Antiviral agents
Antiviral drugs
Clinical trials
Coronaviruses
COVID-19
Eating disorders
Headache
Humanities and Social Sciences
Imipramine
Mental depression
Middle East respiratory syndrome
Migraine
multidisciplinary
Neuralgia
Pandemics
Paroxetine
Patients
Prophylaxis
Science
Science (multidisciplinary)
Sertraline
Severe acute respiratory syndrome coronavirus 2
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQpUpcEE8RKMhI3CBq_IidcIOqVcWBA6JSb5ZfKZFWSZVsDv0X_GRmnOzSVKJcOO5m7E08M5mZ9edvCHlfONYozXxuJYu51I3LKy9sroWMtVQVK2NC-X5T5xfy62V5eavVF2LCZnrgeeGOtQ3w_uROcA-h3SrkY_NB6II55mqX2Esh5t0qpmZWb15LVi-nZApRHY8QqfA0GdReTEPcy9UqEiXC_lWWeRcjeWejNMWfs8fk0ZI40s_zDT8hD2L3lBzOrSRvnpFf33s3jVsKC9UibndD8cQCNoagfUPBrMDcNjcUYa_wnnAxJMkFB4tYGGqvbAu5IsUTw9i5CAYNkKbDZNMYx0-07ShMN_QwMOCHsd2AFdEwTFd0iNegsB7_d6DjjEx8Ti7OTn-cnOdLt4Xcl0xv8zrUDbi_KCJreBGEa3SEcspLV5Ya0jREbmpbRaYDC5A0QeFkmfcygmCAOkO8IAdd38WXhCqueSx4I5RV0uNqe9k4haVkFDbYjLDdyhu_UJFjR4yNSVviojKztgxoyyRtGZWRD_sx1zMRx73SX1Che0kk0U5fgGmZxbTMv0wrI0c7czCLZ4-Gq7qsIM8tZUbe7S-DT-JGi-1iPyUZmEzqgmdEr8xodUPrK137M7F71wL3XGD2jzuD-_Pjf3_gV__jgV-ThxwdpNA5r47IwXaY4hvIubbubXKv361TKZQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9QwDI5gERIXxFMUFhQkbhBt82jSckGAWK04cECsNLcqrw6VRu3QTg_7L_jJ2GlnVrMSe5zWyTSxE3-OHZuQd7njjTbcM6t4ZMo0jpVeWmakipXSJS9iivL9oS8u1fdVsVoO3MYlrHK_J6aNOvQez8jPhK6KEvBFoT5t_zCsGoXe1aWExl1yD1OXoVSblTmcsaAXS_FquSuTy_JsBH2Fd8rAAuMGtB_TR_oope0_wpo3IyVvuEuTFjp_RB4u8JF-nvn9mNyJ3RNyfy4oefWU_P3Zu2ncUZiuFqN3NxTvLWB5CNo3FAYKo9hcUQx-hd3CxZAol2hYjIihdm1bQIwU7w1j_SJoNABYh86mMY4fadtR6G7ooWHAH2O7AVmiYZjWdIhbYFuPpw90nOMTn5HL82-_vl6wpeYC8wU3O1aFqoFNQOaRNyIP0jUmglHllSsKA2AN4zeNLSM3gQeATmA-We69ikAYwNqQz8lJ13fxBaFaGBFz0UhttfI42141TqNBGaUNNiN8P_O1XxKSY12MTZ0c47KsZ27VwK06cavWGXl_aLOd03HcSv0FGXqgxFTa6UE_rOtlZdbGBlDQwknhATtajQn_fJAm5467yhUZOd2LQ72s77G-lsaMvD28hpWJ7hbbxX5KNNCZMrnIiDkSo6MPOn7Ttb9Tju9KoucFev-wF7jrP___gF_e_q2vyAOBop8bJspTcrIbpvgaMNXOvUkL5x_t6yHw
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9RADB6VVkhcEE8RWtAgcYOIzCMzSW8Loqr2wAGo1Fs0rywrrZIq2Rz6L_jJ2JNkUSpA4pjEM0nGdsaOP9uEvM0sq5VmLjWShVTq2qaFEybVQoZSqoLlIaJ8v6jLK7m-zq-PCJ9zYSJoP5a0jJ_pGR32oYeNBpPBwHViGratVN0jJ1iqHWT7ZLVaf1sf_qxg7EqycsqQyUTxh8GLXSgW619YmHfxkXeCpHHvuXhEHk5GI12Nj_mYHIXmCbk_tpG8fUp-fm3t0O8pLNIWMbs7itkK2BSCtjWFFwRR291ShLzCN8IGHyknDCziYKjZmC3YiRSzhbFrEQzqwESHyYY-9Od021CYrmthoMeDfrsDCaK-Gza0CzfArBb_OdB-RCU-I1cXn79_ukynTgupy5nep6Uva1B9kQVW88wLW-sArpSTNs81mGiI2tSmCEx75sFgAqfJMOdkAEIPPoZ4To6btgkvCFVc85DxWiijpMPVdrK2Ct3IIIw3CWHzylduKkOO3TB2VQyHi6IauVUBt6rIrUol5N1hzM1YhOOf1B-RoQdKLKAdT7TdppoEqtLGw7bMreAOLEajsMyf80JnzDJb2jwhZ7M4VJNW9xVXZV6AjZvLhLw5XAZ9xCCLaUI7RBqYTOqMJ0QvxGjxQMsrzfZHrOxdCoy3wOzvZ4H7ffO_v_DL_yM_JQ84qkKmU16ckeN9N4RXYFnt7etJlX4BA1whDQ
  priority: 102
  providerName: Springer Nature
Title Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies
URI https://link.springer.com/article/10.1038/s41598-022-17082-6
https://www.proquest.com/docview/2695805454
https://www.proquest.com/docview/2696864702
https://pubmed.ncbi.nlm.nih.gov/PMC9331004
https://doaj.org/article/7ad4712b32c143a68671cd3701b1b9b5
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3ri9NAEF_ugeAX8YnVs6zgN41mH9lNBJFeueMoeMhpod_C7mbTK5TkTFqw_4V_sjObtNLjFPwUksxu2p2ZzG-y8yDkTWxZqTRzkZHMR1KXNkqdMJEW0mdSpSzxIcr3Ul1M5WSWzA7Itt1Rv4Dtna4d9pOaNsv3P39sPoPCf-pSxtMPLRghTBQDt4ppMGmROiTHYJk0djT40sP9rtY3zyTL-tyZu4fu2adQxn8Pe96OnLy1fRqs0vlD8qCHk3TU8f8ROfDVY3KvazC5eUJ-XdV23a4oLN8Co3mXFPMYsF0ErUsKwgZCuNxQDIaFt4f1RaDso2MxQoaauVkAgqSYR4z9jGBQA-AdJlu3vv1IFxWF6ZoaBhZ40i6WIFu0aNZz2vgbYGONXyNo28UrPiXT87Pv44uo78EQuYTpVZQVWQkvBRF7VvK4ELbUHpwsJ22SaABvGM-pTeqZLlgBUArcKcOckx4IC_A-xDNyVNWVf06o4pr7mJdCGSUdrraTpVXoYHphCjMgbLvyuesLlGOfjGUeNspFmnfcyoFbeeBWrgbk7W7MTVee45_Up8jQHSWW1g4X6mae95qaa1OAweZWcAdY0igsAOgKoWNmmc1sMiAnW3HIt-Kac5UlKaDfRA7I691t0FTcfjGVr9eBBiaTOuYDovfEaO8H7d-pFteh5ncmcCcGZn-3Fbg_D__7H37xf-QvyX2OqhDriKcn5GjVrP0rwFwrOySHeqaH5Hg0mnybwPH07PLrFVwdq_EwfMcYBlX7DWhdLy8
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtNAcFWKELwgThEosEjwBFa9h702EkJcVUpLH1Ar5c3s5RApsoOdCOUv-BK-kZm1nSqV6FsfE89OnJ3ZOXYuQl7GhpWpYjbSkvlIqtJEmRU6UkL6XKYZS3zI8j1Jx2fy6ySZ7JC_Qy0MplUOMjEIaldbvCPf52meZGBfJPL94leEU6MwujqM0OjY4sivf4PL1r47_Az0fcX5wZfTT-OonyoQ2YSpZZS7vAQ2F7FnJY-dMKXy4DZYaZJEgTmCGYpKZ54pxxwYB-AgaGat9ADowJ4WgPcauQ6KN0ZnT03U5k4Ho2aS5X1tTiyy_Rb0I9awgcfHFGjbKN3Sf2FMwJZtezEz80J4Nmi9gzvkdm-u0g8df90lO766R250AyzX98mf77VZtUsK5JlhtvCcYp0EjqOgdUlhY2HX5muKybYgnYx3AbLPvsUMHKqnegYWKsU6ZZyXBIsacA4A2ar17Vs6qyiga2pY6PBDO5sD71LXrKa08QtgkxpvO2jb5UM-IGdXQo2HZLeqK_-I0JQr7mNeilSn0uJuW1maFB1YL7TTI8KGnS9s3wAd53DMixCIF1nRUasAahWBWkU6Iq83axZd-49LoT8iQTeQ2Lo7fFE306KXBIXSDgwCbgS3YKvqFBsMWidUzAwzuUlGZG9gh6KXJ21xzv0j8mLzGCQBhnd05etVgAFkUsV8RNQWG2290PaTavYz9BTPBUZ6APubgeHOf_z_f_jx5e_6nNwcn347Lo4PT46ekFscj0GsIp7tkd1ls_JPwZ5bmmfhEFHy46pP7T_BR11r
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtNAcFVSgXhBnCJQYJHgCax4D3ttJIQobdRSFFUVlfpm9nKIFNnBToTyF3wPX8eMj1SpRN_6mHh24uwcO7NzEfImNCyPFbOBlswHUuUmSKzQgRLSpzJOWOSbLN9JfHQuv15EFzvkb18Lg2mVvU5sFLUrLd6Rj3icRgnYF5Ec5V1axOnB-NPiV4ATpDDS2o_TaFnkxK9_g_tWfzw-AFq_5Xx8-P3LUdBNGAhsxNQySF2aA8uL0LOch06YXHlwIaw0UaTANMFsRaUTz5RjDgwFcBY0s1Z6AHRgWwvAe4vsKvSKBmR3_3Byera54cEYmmRpV6kTimRUw2mJFW3g_zEFZ28Qb52GzdCALUv3ap7mlWBtcwaO75N7nfFKP7fc9oDs-OIhud2Os1w_In_OSrOqlxSINcPc4TnFqgkcTkHLnMI2w77N1xRTb0FXGe8ayC4XF_NxqJ7qGdirFKuWcXoSLKrAVQBkq9rXH-isoICuKmGhww_1bA6cTF21mtLKL4BpSrz7oHWbHfmYnN8IPZ6QQVEW_imhMVfchzwXsY6lxd22MjcxurNeaKeHhPU7n9muHTpO5ZhnTVheJFlLrQyolTXUyuIhebdZs2ibgVwLvY8E3UBiI-_mi7KaZp1eyJR2YB5wI7gFy1XH2G7QOqFCZphJTTQkez07ZJ12qbNLWRiS15vHoBcw2KMLX64aGEAmVciHRG2x0dYLbT8pZj-bDuOpwLgPYH_fM9zlj___Dz-7_l1fkTsgsdm348nJc3KXoxSEKuDJHhksq5V_Acbd0rzspIiSHzctuP8A-9djBg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Robust+antiviral+activity+of+commonly+prescribed+antidepressants+against+emerging+coronaviruses%3A+in+vitro+and+in+silico+drug+repurposing+studies&rft.jtitle=Scientific+reports&rft.au=Kutkat%2C+Omnia&rft.au=Moatasim%2C+Yassmin&rft.au=Al%E2%80%90Karmalawy%2C+Ahmed+A.&rft.au=Abulkhair%2C+Hamada+S.&rft.date=2022-07-28&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-022-17082-6&rft.externalDocID=10_1038_s41598_022_17082_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon